APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A phase 2 trial of Vebreltinib in metastatic cancer and thyroid cancer, run by Apollomics Inc., now recruiting.
Overview
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is a phase 2 interventional study registered as NCT03175224 by Apollomics Inc., with 497 participants planned, started 2017-09-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: APL-101 Oral Capsules. Conditions listed: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.
Setting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase
Phase 2
Sponsor
Apollomics Inc.
Registry
Enrolled
497
Similar pages
not linked directly; found by shared links- TreatmentDabrafenib
Shares Thyroid cancer, Metastatic cancer (cancer that has spread).
- TreatmentLarotrectinib
Shares Thyroid cancer, Metastatic cancer (cancer that has spread).